Fesoterodine

CHEMBL1201764 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
411.6 g/mol
LogP
5.5
Phase
4

This medication relaxes the bladder muscle to reduce symptoms of overactive bladder, including frequent urination, urgency, and urge incontinence. It works by blocking muscarinic receptors that trigger unwanted bladder contractions.

Peso molecular

411,6000 g/mol

LogP

5,50

TPSA

49,80 Ų

Regla de cinco de Lipinski

Cumple

Mecanismo de acción

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1

InChI

InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1

Molecular Formula

C26H37NO3

HBD / HBA

1 / 4

Enlaces Rotables

11

Átomos Pesados

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

This medication relaxes the bladder muscle to reduce symptoms of overactive bladder, including frequent urination, urgency, and urge incontinence. It works by blocking muscarinic receptors that trigger unwanted bladder contractions.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Fesoterodine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201764. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6918558. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.